Developer docs
API playgroundTry for free, no card

Search company profiles

Medimaps Group

Full company profile

uuid0002adp

Namestring
Medimaps Group
Legal namestring
Medimaps Group S.A.
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Medimaps Group S.A. is a Swiss med-tech company founded in 2006 and headquartered in Plan-les-Ouates, Geneva, developing AI-powered imaging software for bone microarchitecture analysis and fracture risk assessment. The company's core technology is its proprietary TBS iNsight deep-tech platform, which applies computer vision and predictive analytics to DXA bone densitometry scans to evaluate trabecular bone structure beyond what standard bone mineral density (BMD) measurements capture. The product portfolio is anchored by TBS Osteo (DXA-based fracture risk assessment), expanded in December 2025 with TBS Reveal (X-ray-based opportunistic bone fragility screening), and complemented by TBS Ortho (orthopedic applications). The company also offers CRO services to pharmaceutical companies for bone-health clinical trials.

The company operates a subscription-based software licensing model with quote-based enterprise pricing, supported by 4 dedicated Medicare CPT reimbursement codes in the United States that have seen steadily increasing reimbursement under the Physician Fee Schedule and Outpatient Prospective Payment System. Distribution combines direct enterprise field sales (with a 'Book a demo' motion) and OEM channel partnerships with the three dominant global DXA hardware manufacturers — GE HealthCare, Hologic, and OsteoSys. The technology is FDA 510(k) cleared, CE-marked under EU MDR (notified body 2460), and ISO 13485:2016 certified, with 1,500 peer-reviewed publications and 35 clinical guidelines referencing TBS technology, and approximately 4.5 million TBS procedures performed annually across 90 markets.

In March 2026, Medimaps announced a strategic merger with Copenhagen-based Radiobotics ApS to create the world's first end-to-end musculoskeletal AI ecosystem combining preventive bone-health assessment with trauma-related fracture detection (RBfracture). The combined entity will operate across 90 markets with offices in Geneva (HQ), Wilmington, Delaware, and Copenhagen, leveraging Medimaps' US office for FDA clearance of RBfracture and Radiobotics' Danish office for streamlined CE registration. The transaction remains subject to Danish foreign direct investment approval. Medimaps is privately held, having raised USD 20 million in December 2021 from Swisscanto, Swiss Entrepreneurs Fund, Swisscom Ventures, and Verve Ventures, and has a headcount in the 11-50 range.

Short descriptiontext

Medimaps Group is a Swiss med-tech company that develops AI-powered imaging software for bone microarchitecture analysis and fracture risk assessment using its proprietary Trabecular Bone Score (TBS) technology, serving healthcare providers, radiology departments, and pharmaceutical companies across 90 markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPlan-les-ouates, Switzerland
HQ citystring
Plan-les-ouates
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bone densitometry software, osteoporosis fracture assessment, medical imaging AI, bone microarchitecture analysis, DXA imaging solutions
Industry1 code
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Commercial Physical & Biological Research8731
Product category
Medical Imaging Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1TBS Osteo Software Licensing
TypeSubscription Recurring
Description

AI-powered bone microarchitecture analysis software licensed to healthcare providers for use during DXA bone densitometry scans. Benefits from 4 dedicated CPT codes for Medicare beneficiaries with steadily increasing reimbursement under PFS and OPPS in the USA.

medimaps.ai
2TBS Reveal (X-ray opportunistic screening)
TypeSubscription Recurring
Description

AI-powered software for opportunistic screening using X-ray technology, enabling additional revenue stream from routine X-ray imaging analysis.

medimaps.ai
3CRO Services for Pharma
TypeProfessional Services
Description

Contract research organization services provided to pharmaceutical companies, likely for clinical trials involving bone health therapeutics.

medimaps.ai
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1TBS Osteo
Description

AI-ready technology and state-of-the-art software powered by TBS iNsight to evaluate bone microarchitecture in patients during DXA bone densitometry scan for osteoporosis fracture risk assessment.

medimaps.ai
+3 more records
Core offering1 text field

Medimaps Group develops and commercializes AI-powered medical imaging software that analyzes bone microarchitecture from DXA bone densitometry scans and routine X-rays to predict osteoporosis fracture risk. Its proprietary TBS iNsight platform powers TBS Osteo (DXA-based assessment), TBS Reveal (X-ray opportunistic screening), and TBS Ortho (orthopedic applications), with native integration into GE HealthCare, Hologic, and OsteoSys DXA systems. The company also offers contract research organization (CRO) services to pharmaceutical clients for bone health clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 4.5M worldwide procedures/year using TBS technology
+3 more records
Product overview1 text field

Medimaps Group offers a unified portfolio of AI-powered bone health imaging solutions centered on its proprietary TBS (Trabecular Bone Score) technology platform. The core offering includes TBS Osteo (DXA-based bone microarchitecture analysis), TBS Reveal (X-ray opportunistic screening), and TBS Ortho (orthopedic applications), all powered by the TBS iNsight deep-tech platform. The company also provides CRO services for pharmaceutical research. Following the 2026 merger with Radiobotics, the portfolio expanded to include trauma-related fracture detection (RBfracture), creating an end-to-end musculoskeletal AI ecosystem spanning preventive care and acute fracture assessment across X-ray and DXA modalities. The technology is integrated with major DXA hardware platforms (GE HealthCare, Hologic, Osteosys) and is deployed across 90 countries with reimbursement support in the United States.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Radiobotics ApS
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic merger agreement to create world's first end-to-end MSK AI ecosystem combining bone microarchitecture analysis with trauma-related fracture detection. Combined entity will serve 90 markets worldwide. Radiobotics will leverage Medimaps' U.S. office for FDA clearance; Medimaps will use Radiobotics' Danish office for CE registration. Transaction subject to Danish FDI approval.

medimaps.ai
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Global DXA partner displaying Medimaps' TBS technology integration with GE HealthCare bone densitometry systems.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Global DXA partner displaying Medimaps' TBS technology integration with Hologic bone densitometry systems.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Global DXA partner displaying Medimaps' TBS technology integration with OsteoSys bone densitometry systems.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Radiobotics
TypeDirect peer
Description

Denmark-based AI medical imaging company developing RBfracture, an AI-powered fracture detection solution for trauma X-ray. Radiobotics is the announced merger partner of Medimaps Group, making it the closest direct peer in MSK AI imaging on the trauma-detection side.

TypeBroad incumbent
Description

Global medical imaging and DXA equipment manufacturer that integrates or distributes Medimaps' TBS software alongside its bone densitometry hardware. A broad incumbent that overlaps with Medimaps in the bone-health workflow while also serving a far wider imaging portfolio.

TypeBroad incumbent
Description

Major women's health and DXA manufacturer whose bone densitometry systems integrate with Medimaps' TBS technology. Comparable as a DXA channel partner and broader incumbent in bone health diagnostics.

TypeDirect peer
Description

AI medical imaging company best known for BoneView, an AI fracture detection solution on routine X-ray. Highly comparable to Medimaps on AI-enabled bone imaging, with overlapping MSK use cases and radiology customer base.

TypeBroad incumbent
Description

South Korea-based AI medical imaging company with FDA-cleared solutions across cancer detection and chest X-ray. Comparable as an established AI imaging vendor with regulatory clearances and global distribution, though focused outside MSK.

TypeBroad incumbent
Description

AI medical imaging platform serving hospitals with FDA-cleared algorithms across multiple body parts and modalities. Comparable as a broad AI imaging incumbent pursuing enterprise health-system deals in the same clinical buyer base.

TypeBroad incumbent
Description

AI medical imaging company with FDA-cleared solutions across chest X-ray, head CT, and musculoskeletal imaging. Comparable as a multi-modality AI imaging vendor with regulatory clearances targeting similar radiology customers.

TypeEmerging player
Description

AI medical imaging company providing comprehensive X-ray and CT decision-support tools, with a fracture and MSK module. Comparable as an emerging AI imaging player with overlapping bone-related use cases on routine X-ray.

TypeRegional player
Description

South Korea-based DXA bone densitometry manufacturer that integrates and distributes Medimaps' TBS software. Comparable as a regional DXA partner with strong Asia-Pacific presence, distinct from GE HealthCare and Hologic's global footprint.

TypeEmerging player
Description

AI-focused orthopedic and bone imaging company developing 3D and weight-bearing CT imaging solutions. Comparable as an emerging player in AI-driven bone and MSK imaging targeting orthopedic and radiology customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medimaps Group

Medical Imaging Softwaremedimapsgroup.com

Medimaps Group is a Swiss med-tech company that develops AI-powered imaging software for bone microarchitecture analysis and fracture risk assessment using its proprietary Trabecular Bone Score (TBS) technology, serving healthcare providers, radiology departments, and pharmaceutical companies across 90 markets.

What Medimaps Group does

Medimaps Group S.A. is a Swiss med-tech company founded in 2006 and headquartered in Plan-les-Ouates, Geneva, developing AI-powered imaging software for bone microarchitecture analysis and fracture risk assessment. The company's core technology is its proprietary TBS iNsight deep-tech platform, which applies computer vision and predictive analytics to DXA bone densitometry scans to evaluate trabecular bone structure beyond what standard bone mineral density (BMD) measurements capture. The product portfolio is anchored by TBS Osteo (DXA-based fracture risk assessment), expanded in December 2025 with TBS Reveal (X-ray-based opportunistic bone fragility screening), and complemented by TBS Ortho (orthopedic applications). The company also offers CRO services to pharmaceutical companies for bone-health clinical trials.

The company operates a subscription-based software licensing model with quote-based enterprise pricing, supported by 4 dedicated Medicare CPT reimbursement codes in the United States that have seen steadily increasing reimbursement under the Physician Fee Schedule and Outpatient Prospective Payment System. Distribution combines direct enterprise field sales (with a 'Book a demo' motion) and OEM channel partnerships with the three dominant global DXA hardware manufacturers — GE HealthCare, Hologic, and OsteoSys. The technology is FDA 510(k) cleared, CE-marked under EU MDR (notified body 2460), and ISO 13485:2016 certified, with 1,500 peer-reviewed publications and 35 clinical guidelines referencing TBS technology, and approximately 4.5 million TBS procedures performed annually across 90 markets.

In March 2026, Medimaps announced a strategic merger with Copenhagen-based Radiobotics ApS to create the world's first end-to-end musculoskeletal AI ecosystem combining preventive bone-health assessment with trauma-related fracture detection (RBfracture). The combined entity will operate across 90 markets with offices in Geneva (HQ), Wilmington, Delaware, and Copenhagen, leveraging Medimaps' US office for FDA clearance of RBfracture and Radiobotics' Danish office for streamlined CE registration. The transaction remains subject to Danish foreign direct investment approval. Medimaps is privately held, having raised USD 20 million in December 2021 from Swisscanto, Swiss Entrepreneurs Fund, Swisscom Ventures, and Verve Ventures, and has a headcount in the 11-50 range.

Medimaps Group firmographics

Firmographics
Name
Medimaps Group
Legal name
Medimaps Group S.A.
Website
https://medimapsgroup.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
51–100 employees
Short description
Medimaps Group is a Swiss med-tech company that develops AI-powered imaging software for bone microarchitecture analysis and fracture risk assessment using its proprietary Trabecular Bone Score (TBS) technology, serving healthcare providers, radiology departments, and pharmaceutical companies across 90 markets.
Ownership category
akta.pro rank

Medimaps Group industry classification

Industry
Product category
Medical Imaging Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Bone densitometry software
  • Osteoporosis fracture assessment
  • Medical imaging AI
  • Bone microarchitecture analysis
  • DXA imaging solutions

Where Medimaps Group is headquartered

Location

Headquarters

HQ city
Plan-les-ouates
HQ country
Switzerland
HQ region
Europe

Offices3 records

Markets served

Medimaps Group business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. TBS Osteo Software Licensing: AI-powered bone microarchitecture analysis software licensed to healthcare providers for use during DXA bone densitometry scans. Benefits from 4 dedicated CPT codes for Medicare beneficiaries with steadily increasing reimbursement under PFS and OPPS in the USA.
  2. TBS Reveal (X-ray opportunistic screening): AI-powered software for opportunistic screening using X-ray technology, enabling additional revenue stream from routine X-ray imaging analysis.
  3. CRO Services for Pharma: Contract research organization services provided to pharmaceutical companies, likely for clinical trials involving bone health therapeutics.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Medimaps Group product offering

Product offering

Core offering

Medimaps Group develops and commercializes AI-powered medical imaging software that analyzes bone microarchitecture from DXA bone densitometry scans and routine X-rays to predict osteoporosis fracture risk. Its proprietary TBS iNsight platform powers TBS Osteo (DXA-based assessment), TBS Reveal (X-ray opportunistic screening), and TBS Ortho (orthopedic applications), with native integration into GE HealthCare, Hologic, and OsteoSys DXA systems. The company also offers contract research organization (CRO) services to pharmaceutical clients for bone health clinical trials.

Product overview

Medimaps Group offers a unified portfolio of AI-powered bone health imaging solutions centered on its proprietary TBS (Trabecular Bone Score) technology platform. The core offering includes TBS Osteo (DXA-based bone microarchitecture analysis), TBS Reveal (X-ray opportunistic screening), and TBS Ortho (orthopedic applications), all powered by the TBS iNsight deep-tech platform. The company also provides CRO services for pharmaceutical research. Following the 2026 merger with Radiobotics, the portfolio expanded to include trauma-related fracture detection (RBfracture), creating an end-to-end musculoskeletal AI ecosystem spanning preventive care and acute fracture assessment across X-ray and DXA modalities. The technology is integrated with major DXA hardware platforms (GE HealthCare, Hologic, Osteosys) and is deployed across 90 countries with reimbursement support in the United States.

Differentiator

Problem solved

Functional benefit

Brands

  • TBS Osteo: AI-ready technology and state-of-the-art software powered by TBS iNsight to evaluate bone microarchitecture in patients during DXA bone densitometry scan for osteoporosis fracture risk assessment.
  • TBS Ortho
  • TBS Reveal
  • CRO services for pharma

Quantifiable outcome

  • 4.5M worldwide procedures/year using TBS technology
  • +3 more outcomes

Companies that use Medimaps Group

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Medimaps Group technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

Feature4 records

Medimaps Group partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and major.

  • Radiobotics ApScoreStrategic or Co-development PartnerStrategic merger agreement to create world's first end-to-end MSK AI ecosystem combining bone microarchitecture analysis with trauma-related fracture detection. Combined entity will serve 90 markets worldwide. Radiobotics will leverage Medimaps' U.S. office for FDA clearance; Medimaps will use Radiobotics' Danish office for CE registration. Transaction subject to Danish FDI approval.
  • GE HealthCaremajorChannel Partner/ Reseller/ DistributorGlobal DXA partner displaying Medimaps' TBS technology integration with GE HealthCare bone densitometry systems.
  • HologicmajorChannel Partner/ Reseller/ DistributorGlobal DXA partner displaying Medimaps' TBS technology integration with Hologic bone densitometry systems.
  • OsteoSysmajorChannel Partner/ Reseller/ DistributorGlobal DXA partner displaying Medimaps' TBS technology integration with OsteoSys bone densitometry systems.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Medimaps Group competitors and assessment

Company assessment

Direct peers

  • Radiobotics: Denmark-based AI medical imaging company developing RBfracture, an AI-powered fracture detection solution for trauma X-ray. Radiobotics is the announced merger partner of Medimaps Group, making it the closest direct peer in MSK AI imaging on the trauma-detection side.
  • Gleamer: AI medical imaging company best known for BoneView, an AI fracture detection solution on routine X-ray. Highly comparable to Medimaps on AI-enabled bone imaging, with overlapping MSK use cases and radiology customer base.

Broad incumbents

  • GE HealthCare: Global medical imaging and DXA equipment manufacturer that integrates or distributes Medimaps' TBS software alongside its bone densitometry hardware. A broad incumbent that overlaps with Medimaps in the bone-health workflow while also serving a far wider imaging portfolio.
  • Hologic: Major women's health and DXA manufacturer whose bone densitometry systems integrate with Medimaps' TBS technology. Comparable as a DXA channel partner and broader incumbent in bone health diagnostics.
  • Lunit: South Korea-based AI medical imaging company with FDA-cleared solutions across cancer detection and chest X-ray. Comparable as an established AI imaging vendor with regulatory clearances and global distribution, though focused outside MSK.
  • Aidoc: AI medical imaging platform serving hospitals with FDA-cleared algorithms across multiple body parts and modalities. Comparable as a broad AI imaging incumbent pursuing enterprise health-system deals in the same clinical buyer base.
  • Qure.ai: AI medical imaging company with FDA-cleared solutions across chest X-ray, head CT, and musculoskeletal imaging. Comparable as a multi-modality AI imaging vendor with regulatory clearances targeting similar radiology customers.

Emerging players

  • Annalise.ai: AI medical imaging company providing comprehensive X-ray and CT decision-support tools, with a fracture and MSK module. Comparable as an emerging AI imaging player with overlapping bone-related use cases on routine X-ray.
  • CurveBeam AI: AI-focused orthopedic and bone imaging company developing 3D and weight-bearing CT imaging solutions. Comparable as an emerging player in AI-driven bone and MSK imaging targeting orthopedic and radiology customers.

Regional players

  • OsteoSys: South Korea-based DXA bone densitometry manufacturer that integrates and distributes Medimaps' TBS software. Comparable as a regional DXA partner with strong Asia-Pacific presence, distinct from GE HealthCare and Hologic's global footprint.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Medimaps Group social profiles

Digital presence

Medimaps Group compliance and trust

Trust signal

Compliance3 records

Medimaps Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medimaps Group leadership team

Management profile

Number of profiles

Medimaps Group subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Medimaps Group funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medimaps Group M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medimaps Group

What does Medimaps Group do?

Medimaps Group develops and commercializes AI-powered medical imaging software that analyzes bone microarchitecture from DXA bone densitometry scans and routine X-rays to predict osteoporosis fracture risk. Its proprietary TBS iNsight platform powers TBS Osteo (DXA-based assessment), TBS Reveal (X-ray opportunistic screening), and TBS Ortho (orthopedic applications), with native integration into GE HealthCare, Hologic, and OsteoSys DXA systems. The company also offers contract research organization (CRO) services to pharmaceutical clients for bone health clinical trials.

Is Medimaps Group a public or private company?

Medimaps Group is a private company. It is classified as venture growth investor backed and is currently operating.

When was Medimaps Group founded?

Medimaps Group was founded in 2006. It employs 51 to 100 people.

Where is Medimaps Group based?

Medimaps Group is headquartered in Plan-les-ouates, Switzerland, in the Europe region.

How does Medimaps Group make money?

Three revenue lines are on record. TBS Osteo Software Licensing is the primary driver. The others are TBS Reveal (X-ray opportunistic screening) and CRO Services for Pharma.

Who are Medimaps Group's main competitors?

Direct peers on record are Radiobotics and Gleamer. Broad incumbents are GE HealthCare, Hologic, Lunit, Aidoc and Qure.ai. Emerging players are Annalise.ai and CurveBeam AI. OsteoSys is listed as a regional player.

Does Medimaps Group have an API?

No public API is recorded for Medimaps Group.

What industry is Medimaps Group in?

Medimaps Group's product category is Medical Imaging Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 541714 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Signify ResearchMedical Imaging AI: Key Acquisitions, Partnerships & FDA Breakthrough UpdatesMarch 2026 saw continued momentum across medical imaging AI at ECR, with consolidation through M&A, platform ecosystem expansion, and deeper integration of AI into imaging IT infrastructure. Key acquisitions included RadNet's purchase of Gleamer for up to €230 million and Sectra's acquisition of Oxipit, while Medimaps Group and Radiobotics announced a strategic merger to combine MSK imaging AI portfolios. On the regulatory front, Harrison.ai received FDA 510(k) clearance for acute infarct triage on non-contrast CT brain scans, and Radiology Partners secured FDA Breakthrough Device designation for its generative AI chest X-ray solution.startupticker.chRadiobotics to join Medimaps GroupMedimaps Group S.A. (Switzerland) and Radiobotics ApS (Denmark) have entered into a strategic merger agreement to create the world's first end-to-end musculoskeletal AI ecosystem, combining AI-powered fracture detection with bone microarchitecture imaging solutions. The combined entity will leverage both companies' clinical expertise and established distribution networks to serve 90 markets worldwide. The transaction is subject to Danish foreign direct investment approval and other customary closing conditions, with financial terms undisclosed.Med-Tech InsightsMedimaps Group and Radiobotics merge to expand musculoskeletal imaging portfolioMedimaps Group S.A. and Radiobotics ApS have announced a strategic merger agreement to combine their AI-driven musculoskeletal imaging businesses, creating what they claim is the world's first end-to-end MSK AI ecosystem. The merged entity will offer a comprehensive suite of AI-enabled imaging solutions across X-ray and DXA modalities, ranging from automated fracture detection to fracture risk prediction, leveraging combined clinical expertise and distribution networks spanning 90 markets worldwide. The transaction is subject to Danish foreign direct investment approval and other customary closing conditions.Business Wire BlogMedimaps Group and Radiobotics Announce Strategic Merger to Expand AI-Driven Musculoskeletal Imaging PortfolioMedimaps Group S.A. and Radiobotics ApS have announced a strategic merger agreement to combine their AI-driven musculoskeletal imaging portfolios, creating what they claim is the world's first end-to-end MSK AI ecosystem. The merged entity will integrate fracture detection and risk prediction tools across X-ray and DXA modalities, leveraging combined clinical validation and distribution networks across 90 markets worldwide including the United States. The transaction is subject to Danish foreign direct investment approval and other customary closing conditions, with financial terms undisclosed.RadioboticsMedimaps Group and Radiobotics announce strategic mergerMedimaps Group S.A. and Radiobotics ApS have announced a strategic merger agreement to create an integrated AI-powered musculoskeletal imaging platform, combining bone microarchitecture analysis with trauma-related fracture detection solutions. The combined entity will offer AI-enabled imaging tools across X-ray and DXA modalities and leverage both companies' distribution networks to serve 90 markets worldwide, including the United States. The transaction is subject to Danish foreign direct investment approval and customary closing conditions, with financial terms undisclosed.Business Wire BlogMEDIMAPS GROUP Raises $20 Million to Expand and to Commercialize AI Product Portfolio for Bone Health Assessment Utilizing Routine Medical ImagesMedimaps Group raised $20 million in an institutional investment round led by Swisscanto Invest. The funds will expand its AI bone health assessment products, with its flagship TBS iNsight receiving U.S. reimbursement starting January 1, 2022.Business Wire BlogMEDIMAPS GROUP Raises $20 Million to Expand and to Commercialize AI Product Portfolio for Bone Health Assessment Utilizing Routine Medical ImagesMEDIMAPS GROUP secured $20 million in an institutional investment round led by Swisscanto Invest to expand its AI product portfolio for bone health assessment. The funding will support the development and market launch of patented AI applications across the U.S., Europe, Asia, and Latin America. This expansion follows the recent medical reimbursement approval for its flagship TBS iNsight product in the United States.startupticker.chDigital Health Company Medimaps Raises $20 MillionMedimaps Group secured $20 million in an institutional investment round led by Swisscanto Invest to expand its TBS iNsight product portfolio. The funding follows the product's medical reimbursement approval in the U.S. starting January 1, 2022, enabling broader market expansion across the U.S., Europe, Asia, and Latin America. This capital will support the development and marketing of deep tech bone texture analysis solutions aimed at improving osteoporosis diagnosis rates.VerveMedimaps Group raises USD 20 millionMedimaps Group secured USD 20 million in a financing round led by Swisscanto, alongside Swiss Entrepreneurs Fund, Swisscom Ventures, and Verve Ventures. The company plans to use these funds to expand its product portfolio and launch patented AI applications for bone health assessment in the U.S., Europe, Asia, and Latin America.